Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Lexaria Bioscience Corp (LEXXW)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/24/2024: LEXXW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -68.56% | Upturn Advisory Performance  1 | Avg. Invested days: 22 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 12/24/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -68.56% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 12/24/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.79M USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 3737 | Beta 1.06 |
52 Weeks Range 0.43 - 2.50 | Updated Date 12/25/2024 |
Company Size Small-Cap Stock | Market Capitalization 33.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 3737 | Beta 1.06 |
52 Weeks Range 0.43 - 2.50 | Updated Date 12/25/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2074.9% |
Management Effectiveness
Return on Assets (TTM) -38.21% | Return on Equity (TTM) -70.66% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating 13225553 |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13225553 |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile:
Lexaria Bioscience Corp is a US-based biotechnology company specializing in the development of proprietary delivery technology for the pharmaceutical and cannabis industries. The company was founded in 2004 and is headquartered in British Columbia, Canada. Lexaria Bioscience Corp focuses on enhancing the delivery of bioactive compounds through its patented DehydraTECHTM technology, which improves the absorption and effectiveness of orally consumed products.
The core business areas of Lexaria Bioscience Corp include research and development of its delivery technology, licensing its technology to partners in various industries, and the commercialization of its own branded products.
The leadership team of Lexaria Bioscience Corp is led by CEO and Chairman, Chris Bunka, who has over 20 years of experience in the biotechnology and pharmaceutical sectors. The company's corporate structure includes key executives responsible for research and development, operations, and business development.
Top Products and Market Share:
Lexaria Bioscience Corp's top products include DehydraTECHTM-powered oral products in the pharmaceutical and cannabis industries. These products have gained traction in the global market due to their ability to improve bioavailability and reduce onset times compared to traditional delivery methods.
The market share of Lexaria Bioscience Corp's products in the global and US markets is steadily growing as the company secures new partnerships and expands its product portfolio. While the company faces competition from other delivery technology companies, its unique DehydraTECHTM platform has positioned it as a leader in the industry.
Total Addressable Market:
The total addressable market for Lexaria Bioscience Corp includes the pharmaceutical, cannabis, and nutraceutical industries. With the increasing demand for more effective and efficient delivery methods for bioactive compounds, the company's technology has the potential to capture a significant portion of these markets.
Financial Performance:
Recent financial statements show that Lexaria Bioscience Corp has experienced consistent revenue growth over the past few years, driven by increased licensing agreements and product sales. The company has also demonstrated improved profit margins and positive earnings per share (EPS), indicating strong financial health and operational efficiency.
Dividends and Shareholder Returns:
Lexaria Bioscience Corp does not currently pay dividends as it reinvests its profits back into research and development initiatives. However, the company has generated positive total shareholder returns over the past few years, driven by its growth prospects and market positioning.
Growth Trajectory:
Historically, Lexaria Bioscience Corp has shown steady growth over the past 5 to 10 years as it continues to innovate and expand its product offerings. Future growth projections are optimistic, with the company focusing on new market opportunities and strategic partnerships to drive expansion.
Market Dynamics:
Lexaria Bioscience Corp operates in a dynamic industry that is characterized by evolving regulations, technological advancements, and changing consumer preferences. The company is well-positioned within the industry due to its innovative delivery technology and its ability to adapt to market changes.
Competitors:
Key competitors of Lexaria Bioscience Corp include GW Pharmaceuticals (GWPH) and Canopy Growth Corporation (CGC). While these competitors also focus on pharmaceutical and cannabis delivery technologies, Lexaria Bioscience Corp stands out due to its unique DehydraTECHTM platform and its growing market presence.
Potential Challenges and Opportunities:
Key challenges for Lexaria Bioscience Corp include regulatory hurdles, competitive pressures, and the need to continuously innovate to maintain its market leadership. However, the company also has opportunities to expand into new markets, develop new products, and form strategic partnerships to drive growth.
Recent Acquisitions (last 3 years):
Lexaria Bioscience Corp has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on AI-based fundamental analysis, Lexaria Bioscience Corp receives a rating of 7 out of 10. This rating is justified by the company's strong financial performance, market positioning, and growth prospects, although there are challenges such as regulatory uncertainties and competitive pressures to consider.
Sources and Disclaimers:
Sources used for this analysis include Lexaria Bioscience Corp's official website, financial statements, industry reports, and news articles. This information is provided for informational purposes only and should not be considered as investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
| Exchange | NASDAQ | Headquaters | Kelowna, BC, Canada |
| IPO Launch date | 2021-01-12 | CEO | - |
| Sector | Healthcare | Website | https://lexariabioscience.com |
| Industry | Biotechnology | Full time employees | 5 |
| Headquaters | Kelowna, BC, Canada | ||
| CEO | - | ||
| Website | https://lexariabioscience.com | ||
| Website | https://lexariabioscience.com | ||
| Full time employees | 5 |
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.